BioLineRx (NASDAQ: BLRX) director details extensive stock option grants

Rhea-AI Filing Summary

BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider Molcho Avraham

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 49,800 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Key Figures

Largest option block: 2,055,000 underlying shares at $0.052 2022 option grant: 1,080,000 underlying shares at $0.085 2023 option grant: 360,000 underlying shares at $0.081 +5 more

8 metrics

Largest option block 2,055,000 underlying shares at $0.052 Employee stock option expiring August 14, 2034

2022 option grant 1,080,000 underlying shares at $0.085 Employee stock option expiring July 3, 2032

2023 option grant 360,000 underlying shares at $0.081 Employee stock option expiring July 3, 2033

2024 option grant 360,000 underlying shares at $0.085 Employee stock option expiring July 3, 2032

2019 option grant 199,800 underlying shares at $0.356 Employee stock option expiring July 2, 2029

Earliest option grant 49,800 underlying shares at $0.837 Employee stock option expiring July 5, 2026

Immediate vest portion (2025 grant) 856,200 options Vested on October 1, 2024 appointment date

Unvested portion (2025 grant) 1,198,800 options To vest in 7 equal quarterly installments

Key Terms

Employee Stock Option (Right to Buy), underlying security, 2003 Amended and Restated Share Incentive Plan, vested, +2 more

6 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

underlying security financial

""underlying_security_title": "Ordinary Shares""

2003 Amended and Restated Share Incentive Plan financial

""Options granted under the 2003 Amended and Restated Share Incentive Plan.""

vested financial

""This option grant is fully vested as of this date.""

Section 102 of the Israeli Tax Ordinance financial

""To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance""

trustee financial

""securities issued to an employee... must be registered in the name of a trustee""

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Molcho Avraham

(Last) (First) (Middle)

C/O BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/05/2016	07/05/2026	Ordinary Shares	49,800(12)	$0.837	D
Employee Stock Option (Right to Buy)(1)(3)	10/05/2017	07/05/2027	Ordinary Shares	19,800(12)	$0.92	D
Employee Stock Option (Right to Buy)(1)(4)	10/05/2018	07/05/2028	Ordinary Shares	19,800(12)	$0.894	D
Employee Stock Option (Right to Buy)(1)(5)	10/02/2019	07/02/2029	Ordinary Shares	199,800(12)	$0.356	D
Employee Stock Option (Right to Buy)(1)(6)	10/02/2020	07/02/2030	Ordinary Shares	79,800(12)	$0.369	D
Employee Stock Option (Right to Buy)(1)(7)	10/02/2021	07/02/2031	Ordinary Shares	79,800(12)	$0.388	D
Employee Stock Option (Right to Buy)(1)(8)	10/03/2022	07/03/2032	Ordinary Shares	1,080,000(12)	$0.085	D
Employee Stock Option (Right to Buy)(1)(9)	10/03/2023	07/03/2033	Ordinary Shares	360,000(12)	$0.081	D
Employee Stock Option (Right to Buy)(1)(10)	10/03/2024	07/03/2032	Ordinary Shares	360,000(12)	$0.085	D
Employee Stock Option (Right to Buy)(1)(11)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000(12)	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date.

4. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date.

5. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date.

7. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date.

8. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.

9. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.

10. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.

11. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

12. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Avraham Molcho	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioLineRx (BLRX) director Molcho Avraham report in this Form 3?

Molcho Avraham reports existing holdings of employee stock options to buy BioLineRx Ordinary Shares. These options were granted under the company’s 2003 Amended and Restated Share Incentive Plan, with various exercise prices and expiration dates, and represent his current derivative equity position.

How many BioLineRx shares are covered by Molcho Avraham’s largest option grant?

The largest reported option grant covers 2,055,000 underlying Ordinary Shares at an exercise price of $0.052 per share. This grant expires on August 14, 2034 and is part of Avraham’s compensation-based equity awards.

Are Molcho Avraham’s BioLineRx stock options already vested?

Several grants are fully vested, including options granted between July 2016 and July 2024. For the October 1, 2024 grant, 856,200 options vested immediately, while 1,198,800 options vest in seven equal quarterly installments, subject to continued service.

What are the exercise prices on Molcho Avraham’s BioLineRx stock options?

The reported employee stock options have exercise prices ranging from $0.052 to $0.920 per Ordinary Share. Each grant has a specific strike price and expiration date, reflecting awards made over multiple years under the company’s share incentive plan.

When do Molcho Avraham’s BioLineRx stock options expire?

The option grants expire on dates between July 5, 2026 and August 14, 2034, depending on the original grant. Earlier grants from 2016–2018 expire in 2026–2028, while more recent low‑priced awards extend into the early 2030s if not exercised.

Under which plan were Molcho Avraham’s BioLineRx options granted?

All reported options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. This plan governs the terms, vesting schedules, and tax-related arrangements for employee equity awards, including the use of a trustee structure for certain Israeli tax benefits.